Quality of life in dermatomyositis - 12/11/11
Reprint requests: Victoria Werth, MD, Department of Dermatology, Perelman Center for Advanced Medicine, Suite 1-330A, 3400 Civic Center Blvd, Philadelphia, PA 19104.Abstract |
Background |
Quality of life (QoL) for patients with inflammatory skin disease can be significant, but has been evaluated in just one study in dermatomyositis (DM).
Objective |
We sought to examine the relationship between the Cutaneous Dermatomyositis Area (CDASI) and Severity Index, a DM-specific cutaneous severity instrument, and various QoL study instruments and to determine the impact of DM on QoL.
Methods |
Skin-specific QoL instruments, the Skindex and the Dermatology Life Quality Index, and global medical QoL instruments, the Short Form 36 and the Health Assessment Questionnaire-Disability Index, were used. Pruritus was evaluated by a visual analog scale and a 0-to-10 scale in DM and cutaneous lupus erythematosus (CLE) populations, respectively.
Results |
There was a significant correlation between the CDASI and all skin-specific QoL scores (lowest P = .0377). Using the Short Form 36, DM population was found to have significantly worse QoL scores than the general population with the exception of bodily pain (all subscore P values < .01). Furthermore, DM had a significantly lower vitality score, representing energy level, compared with CLE, hypertension, diabetes, and recent myocardial infarction scores (lowest P = .003). There was a significantly lower mental health score, representing overall mood, to all compared diseases except CLE and clinical depression (P values < .01 when significant). We found that DM produces more pruritus than CLE (P < .0001).
Limitations |
A larger patient population needs to be studied to further assess QoL in patients with DM.
Conclusion |
We conclude that DM has a large impact on QoL, even when compared with other diseases, and that DM skin disease activity correlates with a poorer QoL.
Le texte complet de cet article est disponible en PDF.Key words : autoimmune disease, clinical research, connective tissue disease, cutaneous lupus, dermatomyositis, itch, pruritus, quality of life
Abbreviations used : CDASI, CDM, CLE, CTCL, DLQI, DM, HAQ, HAQ-DI, HTN, MH, NMSC, PGA, PtGA, QoL, RE, SF-36, SLE, VAS
Plan
| This material is based on work supported by the National Institutes of Health (NIH), including NIH K24-AR 02207 (Dr Werth) and training grant NIH 5-R25-HL084665-04 (Dr Goreshi). This work was also partially supported by a Merit Review Grant from the Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. |
|
| Disclosure: Dr Fiorentino received honoraria from Amgen, Centocor, Chemocentryx, and MedImmune; received grants from Centocor, Abbott Laboratories, and Amgen; and filed a patent (US patent application serial number 12/694,980 for “Profiling for Determination of Response to Treatment for Inflammatory Disease” filed on January 27, 2010). Drs Goreshi, Chock, Feng, and Werth, Ms Foering, Ms Okawa, and Mr Rose have no conflicts of interest to declare. |
Vol 65 - N° 6
P. 1107-1116 - décembre 2011 Retour au numéro
Article précédent
- Nephrogenic systemic fibrosis: Clinicopathological definition and workup recommendations
- Michael Girardi, Jonathan Kay, Dirk M. Elston, Philip E. LeBoit, Ali Abu-Alfa, Shawn E. Cowper
- The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system
- Janet Shin, T. Craig Cheetham, Linda Wong, Fang Niu, Elizabeth Kass, Monica A. Yoshinaga, Mike Sorel, Jeffrey S. McCombs, Stephen Sidney
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?